NCT05117177View on ClinicalTrials.gov

New Formulation Study of Inupadenant (EOS100850) in Patients with Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

July 1, 2021

Primary Completion Date

May 9, 2024

Study Completion Date

May 9, 2024

Conditions
Solid Tumor, Adult
Interventions
DRUG

Inupadenant

Oral administration

DRUG

Inupadenant

Oral administration

DRUG

Inupadenant

Oral administration

Trial Locations (5)

1070

Institut Jules Bordet, Anderlecht

1200

Cliniques Universitaires St-Luc, Brussels

2610

GZA Ziekenhuizen, Wilrijk

9000

University Hospital Ghent, Ghent

SM2 5PT

Royal Marsden NHS Foundation Trust, Sutton

Sponsors

Lead Sponsor

iTeos Therapeutics
All Listed Sponsors
collaborator

iTeos Belgium SA

INDUSTRY

lead

iTeos Therapeutics

INDUSTRY

NCT05117177 - New Formulation Study of Inupadenant (EOS100850) in Patients with Cancer | Biotech Hunter | Biotech Hunter